Skip to main content

National Institutes of Health

HIV Prevention and Alcohol (R61/R33 Clinical Trials Optional)

Upcoming

Decision brief

Who can apply
GovernmentHigher EducationSmall BusinessOtherNonprofitsNonprofits (preferred)
Award amount
Not specified
Deadline
Sep 7, 2027
Geography
National
Application notesMedium effort
  • Federal application

Next step

Apply at Grants.gov

View Source

Focus areas

About this grant

This Notice of Funding Opportunity (NOFO) uses a R61/R33 Phased Innovation Award to support milestone-driven research that advances innovative HIV prevention interventions from development and feasibility testing to larger-scale efficacy, effectiveness, implementation, and dissemination studies. The R61 phase will support the development, refinement, adaptation, and pilot testing of novel or enhanced HIV prevention and treatment strategies, including studies designed to address key scientific, operational, or implementation questions necessary to establish feasibility and readiness for larger-scale evaluation. Projects may generate evidence needed to optimize intervention design, delivery, and implementation in diverse populations and settings. The R33 phase will support expanded testing of interventions and implementation strategies that have successfully met R61 milestones. Studies may evaluate effectiveness, implementation, scalability, sustainability, clinical management, or delivery of HIV prevention interventions that include integrated approaches addressing alcohol use and related comorbidities.

Additional details

CFDA / ALN Number
93.273
Program Title
Alcohol Research Programs
Funding Instrument
Grant
Source
Grants.gov · View original listing

Similar grants